Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ticagrelor + aspirin (Laboratorios Silanes)
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRILINTA + ASPIRINA JUNIOR is a fixed-dose combination (FDC) investigational drug product developed by Laboratorios Silanes. It combines 90 mg of ticagrelor, a reversible P2Y12 receptor antagonist, with 100 mg of acetylsalicylic acid (aspirin), a cyclooxygenase (COX) inhibitor. This dual antiplatelet therapy is intended for the treatment of acute coronary syndrome (ACS) and myocardial infarction. By combining these two active ingredients into a single solid oral formulation, the product aims to simplify the dual antiplatelet therapy (DAPT) regimen for patients. The combination has been evaluated in a Phase 1 crossover bioavailability study comparing the FDC formulation against the co-administration of the individual reference monotherapies, Brilinta (AstraZeneca) and Aspirina Junior (Bayer).
- Brand names
- BRILINTA + ASPIRINA JUNIOR
- Other names
- ticagrelor + acetylsalicylic acidticagrelor/ASA FDC
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ENT1 (Solute carrier family 29 member 1)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on ticagrelor + aspirin (Laboratorios Silanes).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ticagrelor + aspirin (Laboratorios Silanes).